Background
Prostate cancer is the most commonly diagnosed malignancy in American men. 1 Detection rates for this disease have been on the rise, most likely because of widespread use of the PSA screening test. According to the American Cancer Society, about 230 110 new cases of prostate cancer are expected in 2004. The majority of prostate cancer cases now are discovered at an early stage when 5-year survival approaches 100%. 1 Even though deaths from prostate cancer have been declining since the early 1990s, prostate cancer, however, is still the second leading cause of cancer death in men. An estimated 29 900 deaths will occur in the US in 2004, accounting for about 10% of cancer deaths. 1 Despite its frequent occurrence, the causes of prostate cancer are not yet completely understood.
In addition to the intracellular sorting of lysosomal enzymes, the mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) plays a critical role in regulating the bioavailability of extracellular proteolytic enzymes and growth factors known to be mechanistically involved in malignant transformation. [2] [3] [4] It is inactivated early in the development of a number of cancers, including those in the liver, breast and lung. [3] [4] [5] [6] [7] [8] M6P/IGF2R mutation furthermore predicts for poor therapeutic outcome. 9 Thus, the M6P/IGF2R gene encodes for a receptor that functions normally to suppress tumor formation.
The constitutive activation or overexpression of protooncogenes and the inactivation of tumor suppressor genes are critical events in the multistep process of carcinogenesis. The M6P/IGF2R gene is located at 6q26, a chromosomal location commonly deleted in cancer. 3, [5] [6] [7] [8] It encodes for a multifunctional receptor required for the intracellular trafficking of lysosomal enzymes to the lysosomes, and the extracellular activation of the growth inhibitor, transforming growth factor b1 (TGFb1), and the degradation of the mitogen, IGF2. 2, 10 Evidence suggests, however, that the M6P/IGF2R is not involved in cell signaling by IGF2. 11 This function is mediated by the insulin-like growth factor 1 receptor (IGF1R) and the insulin receptor isoform A. 12, 13 The M6P/IGF2R therefore functions as a 'guardian of the cell' by controlling the extracellular levels of potent growth factors and proteolytic enzymes that govern cell death, proliferation and invasion. 14 The M6P/IGF2R is inactivated in a variety of human tumors. [5] [6] [7] [8] It is mutated in dysplastic liver lesions and hepatocellular carcinomas (HCCs) of patients with or without hepatitis virus (HV) infection. 5, 6, 8 The gene contains a poly-deoxyguanine (poly-G) region that is a common mutational target in colon, gastric and endometrial tumors with mismatch repair deficiencies and microsatellite instability. [15] [16] [17] It is also mutated in human gliomas that do not contain mutations in either the transforming growth factor b type II receptor or Bax genes. 17 Moreover, the M6P/IGF2R is mutated in 30% of breast tumors and 60% of squamous cell carcinomas of the lung. 7, 18 M6P/IGF2R inactivation is an early transformational event, occurring in the initiation rather than the progression stage of carcinogenesis. 7, 8 This is clearly evident in the development of liver cancer. 4, 8 Clonal expansion of normal appearing, preneoplastic hepatocytes with a single mutated M6P/IGF2R allele often occurs in patients chronically infected with the HVs, HBV and HCV. 8 These precancerous hepatocytes have an enhanced risk of developing into tumors because they ultimately give rise to more than 60% of human HCCs. 5, 6, 8 M6P/IGF2R inactivation is also an early event in breast cancer, 7 and receptor loss correlates with poor differentiation in early breast carcinomas. 19 Moreover, M6P/IGF2R mutation predicts for poor therapeutic outcome in lung and head and neck cancer, suggesting it may be a useful marker for prospectively stratifying patients in adjuvant therapy protocols.
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TGFb1 is an important regulator of the normal and malignant prostate. Prostate cancer cells express high levels of TGFb1, which seems to enhance prostate cancer growth and metastasis by promoting angiogenesis and inhibiting immune responses against the tumor cells. Prostate cancer cells frequently are resistant to the antiproliferative and proapoptotic effects of TGFb1, and these findings are associated with a poor prognosis (reviewed in Wikstrom et al 21 ). The role of the M6P/ IGF2R, which is both a tumor suppressor gene and an important component in the bioavailability of TGFb1, has never been assessed in prostate cancer. It is the goal of this project to determine whether the M6P/IGF2R is inactivated in prostate cancer, and if so, whether this is an early or late transformational event. To address this question, we examined a series of archival prostate specimens from patients who underwent radical prostatectomy for carcinoma of the prostate.
Methods

Patients
Institutional review board approval was obtained for this research protocol. This study used histological sections prepared from tissue blocks of prostates that were removed as part of the patient's medical care, prior to February 2003, that is, the tissues were removed solely for nonresearch purposes. These blocks of tissue were identified by searching the Cerner PathNet database that contains the results of pathological examination of specimens removed at Duke University Medical Center during the past 20 years. The database contains the surgical pathology reports for approximately 485 000 surgical pathology cases (approximately 1.5 million specimens) and approximately 575 000 cytopathology cases. All cases are coded using the Systematized Nomenclature of Medicine (SNOMED) and were retrieved on the basis of the tissue site (topography code) and morphological diagnosis. The complete surgical pathology report and histology slides of possible cases were examined, and cases where the tissue was adequate (the sections are properly oriented, the amount of diseased tissue is adequate, and sufficient tissue remains for preparation of additional sections) were used for this study. Other eligibility criteria included: no evidence of distant metastases before and follow-up 46 months from the date of prostatectomy. A total of 43 patients who underwent radical prostatectomy between April 1992 and July 2001 at Duke University Medical Center were selected for this study
Tissue microdissection and M6P/IGF2R loss of heterozygosity (LOH) analysis
Microdissection of malignant, premalignant and surrounding normal prostate tissue was performed as previously described; 6-8 tumor histology was confirmed by one of two pathologists (SM or JM). Confirmation that the tissue being analyzed was, in fact, normal, malignant, or high-grade prostatic intraepithelial neoplasia (PIN) was made by one board certified pathologist with special expertise in the pathology of genitourinary malignancy (JM). Paraffin-embedded sections (5 mm in thickness) were microdissected following deparaffinization, and the tissue was then digested by proteinase K in Tris-EDTA buffer at 551C for 4 h. In total, 10 different gene-specific single-nucleotide polymorphisms were used to assess prostate tumors for M6P/IGF2R LOH. 22, 23 The 48 individual exons in the M6P/IGF2R with approximately 100 base pair flanking intronic sequences were polymerase chain reaction (PCR)-amplified using samples from 43 patients with prostate cancer identified from the tissue archive. The oligonucleotides used have been previously described. 24 PCRs were performed using 50-100 ng template DNA, 1.5 U Taq DNA polymerase (Perkin Elmer Corporation, Norwalk, CT, USA), 15 pmol primers, 1.5 mM MgCl 2 , and 100 mM dNTPs in a 30 ml PCR reaction volume. Each round of PCR consisted of 35 cycles at 941C for 15 s, 551C for 5s, and 721C for 30s. The amplimers were analyzed and extracted from 2% agarose gel (GenElute, Sigma, St Louis, MO, USA) using the automated ABI PRISM sequencer (PE Applied Biosystems, Foster City, CA, USA), according to the manufacturer's protocol (Figure 1 ). Single-nucleotide polymorphisms were identified as sequence dimorphisms in the sequenced DNA or as di-allelic homozygous alternates. 22 The PCR primers for amplification of the 10 M6P/ IGF2R single-nucleotide polymorphisms are shown in Loss of heterozygosity of M6P/IGF2R gene CK Hu et al Table 1 . The polymorphisms were PCR amplified using conditions identical to those described above. Intronic polymorphisms were amplified using published primers for the nearest exon. 22, 24 Genotypes were confirmed by DNA sequencing.
Taq DNA polymerase can introduce sequence errors during PCR amplification, and unequal amplification of the two alleles during the PCR reaction can result in false positive detection of LOH. Thus, both the normal and tumor DNA templates were amplified in three independent PCR reactions, and assessed for tumor M6P/IGF2R LOH. Due to the potential of contaminating the tumor tissue sample with normal stroma, allele loss in informative patients was defined by calculating the ratio of the 25 ((peak height of normal allele 2)/ (peak height of normal allele 1))/((peak height of tumor allele 2)/(peak height of tumor allele 1)). A ratio of o0.7 or 41.4 was considered a strong indicator of LOH. 25 
Statistical analysis
Pearson w 2 test determined differences in characteristics of the patient groups. One-way ANOVA assessed the significance of these differences. P-values less than 0.05 were considered statistically significant. The KaplanMeier method was used to estimate disease-free survival, and differences were assessed with the log-rank statistic. Since no patient died of prostate cancer only disease-freesurvival was assessed. Data were analyzed by SPSS statistical package (Version 8.0 for Windows; SPSS, Inc., Chicago, IL, USA).
Results
A total of 43 patients with prostate cancer were selected from the tissue archive, of which 36 (83.7%) were polymorphic in the M6P/IGF2R locus. Characteristics of this patient population are described in Table 2 . There was no significant difference in any of the disease characteristics between the groups with or without LOH. The mean follow-up is 75 and 80 months for patients with or without LOH, respectively.
LOH was found not only in prostate cancer, but also in high-grade PIN. The M6P/IGF2R gene was polymorphic in 83.7% (36/43) of patients, and 41.7% (15/36) of these informative patients had LOH in malignant tissue. In 11/ 15 patients with LOH in malignant tissue, high-grade PIN could be identified, and 63.6% (7/11) also had LOH in the premalignant lesion. The most common regions of LOH in both malignant tissue and PIN were in exon 6 and intron 7. In PIN, LOH was not found in exons 16 and 40, or in intron 46. In malignant tissue, LOH was not found in exon 40 (Table 3) . At several loci, LOH was present in tumor, but could not be identified in PIN for a given patient, either due to the absence of PIN in the specimen or because the PIN sample was not informative. Every patient with LOH at a given locus in PIN also demonstrated LOH in tumor at the same locus. Indicates that no PIN could be identified in the archival specimen in one or more patients.
Loss of heterozygosity of M6P/IGF2R gene CK Hu et al
Discussion
The present study is the first to demonstrate that the M6P/IGF2R gene is mutated in prostate cancer. In addition, we show that this is an early transformational event, as indicated by the presence of LOH in preneoplastic prostate cells, and the fact that every patient with LOH in premalignant tissue also demonstrated LOH in tumor at the same locus. Mutations on chromosome 6 appear to be frequent occurrences in prostate cancer. Loss of 6q24-qter has been found in recurrent, androgen-insensitive prostate tumors. 26 In addition, 6q21-6q23 and 6q25-6q27 are two regions with a high frequency of LOH in both prostate cancer and high-grade PIN. 27 The M6P/IGF2R gene is located within these frequently mutated sites, at 6q26, but it had not been previously described as being mutated in prostate cancer. The present study shows that LOH at the M6P/IGF2R locus occurs in both prostate cancer and high-grade PIN. High-grade PIN is a premalignant lesion whose presence specifically portends an increased risk of prostate cancer. 28 Therefore, LOH at M6P/IGF2R locus appears to be an important transformational event development of prostate cancer.
The prognostic significance of mutation of the M6P/ IGF2R gene cannot be definitively determined. In this study, more than half of the mutations were found in tumors, which would be classified as low risk, that is early stage (clinical stage T1 and T2), organ confined, PSA less than 10 ng/ml at diagnosis, Gleason Score equal to or less than 7, diploid tumor, and proliferation index less than 4 (Table 1) . Furthermore, there was no significant difference in disease-free survival between the groups of with or without LOH. Although the duration of follow-up is reasonably long (mean 46 years), the study sample size is small, and the power to detect a difference if one exists is low. Others have found that M6P/IGF2R mutation correlates with high tumor grade (breast cancer) and worse treatment outcome (lung and head/neck cancers). This issue deserves further study in prostate cancer.
Conclusions
In summary, mutation of the M6P/IGF2R is an early transformational event in a significant percentage of prostate cancers. Targeting growth factors regulated by this gene may, in some patients, prove to be a useful therapeutic approach.
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